Protalix BioTherapeutics ... (PLX)
| Bid | 2.94 |
| Market Cap | 233.47M |
| Revenue (ttm) | 53.4M |
| Net Income (ttm) | 2.93M |
| EPS (ttm) | 0.04 |
| PE Ratio (ttm) | 74.8 |
| Forward PE | 3.64 |
| Analyst | Strong Buy |
| Ask | 3.18 |
| Volume | 514,199 |
| Avg. Volume (20D) | 731,352 |
| Open | 3.09 |
| Previous Close | 3.07 |
| Day's Range | 2.97 - 3.09 |
| 52-Week Range | 0.82 - 3.10 |
| Beta | 0.46 |
About PLX
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candi...
Analyst Forecast
According to 1 analyst ratings, the average rating for PLX stock is "Strong Buy." The 12-month stock price forecast is $15, which is an increase of 401.34% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · proactiveinvestors.com
Protalix Biotherapeutics chairman discusses breakthrough in gout treatment, drug pipeline - ICYMIProtalix Biotherapeutics Inc (NYSE-A:PLX) chairman Eliot Forster joined Proactive to discuss the company's unique approach to drug manufacturing using plant cells instead of mammalian cells. He explai...
1 month ago · proactiveinvestors.com
Protalix Biotherapeutics gains momentum: analysts see long-term upsideProtalix Biotherapeutics Inc (NYSE-A:PLX) reported increased product revenues for 2024, driven by higher sales of its Fabry disease treatment, Elfabrio, to partner Chiesi Rare Disease. The company's i...
1 month ago · proactiveinvestors.com
Protalix Biotherapeutics reports record revenue in 2024, advances gout treatment candidateProtalix Biotherapeutics Inc (NYSE-A:PLX) reported record revenue from product sales in 2024, driven by growth across all major commercial partnerships, and provided updates on its clinical pipeline, ...
1 month ago · seekingalpha.com
Protalix BioTherapeutics, Inc. (PLX) Q4 2024 Earnings Call TranscriptProtalix BioTherapeutics, Inc. (NYSE:PLX ) Q4 2024 Earnings Conference Call March 17, 2025 8:30 AM ET Company Participants Mike Moyer - Investor Relations, LifeSci Advisors Dror Bashan - President and...
2 months ago · proactiveinvestors.com
Protalix Biotherapeutics poised for profitability as rare disease drug gains momentumFor a small biotech company, Protalix Biotherapeutics Inc (NYSE-A:PLX) is making a big impression with analysts and investors by targeting rare diseases with cutting-edge treatments. The New Jersey- a...
2 months ago · proactiveinvestors.com
Protalix Biotherapeutics gains momentum in the rare disease space: analystsProtalix Biotherapeutics Inc (NYSE-A:PLX) has received bullish assessments from analysts at HC Wainwright and Zacks Small Cap Research, who see sustainable profitability on the horizon. Strong revenue...